This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

China Diagnostic Reagent Industry Report, 2012-2014

DUBLIN, Ireland, March 26, 2013 /PRNewswire/ --

Research and Markets announces the addition of " China Diagnostic Reagent Industry Report, 2012-2014" to its catalogue.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

China's diagnostic reagent industry has formed a certain market scale and basis, and is marching from the introduction stage to the growth stage. With the continuous growth in China's medical care investment and per capita health care spending, the China's diagnostic reagent market has a promising prospect.

In vitro diagnostic reagents account for more than 90.0% of the output of China's diagnostic reagent industry. In 2011, the market scale of in vitro diagnostic reagents reached about RMB 11.4 billion in China, the industry will maintain a growth rate of 15%-20% in the future, and the market scale will hit RMB 20.8 billion in 2015.

At present, there are only a few integrated in vitro diagnostic reagent enterprises with strong strength in China's diagnostic reagent market, including KHB and Fosun Pharma; other enterprises such as Da An Gene, BioSino, Leadman and Livzon have competitive advantages in specific fields such as biochemical diagnosis, immunodiagnosis, and molecular diagnosis.

Meanwhile, China's in vitro diagnostic reagent industry concentration is low. Among 300-400 enterprises, there are only about 20 enterprises with annual sales of more than RMB 100 million. The enterprises are generally small and have a few product varieties. In 2011, KHB, Da An Gene, BioSino, Leadman only occupied 3.8%, 2.3%, 1.9%, 1.6% of the market respectively. Key Topics Covered:

1. Overview of Diagnostic Reagent Industry 2. China Diagnostic Reagent Industry 2.1 Overview 2.2 Market Structure 2.3 Import and Export 2.3.1 Import 2.3.2 Export 2.4 Competitive Landscape 2.4.1 Biochemical Diagnostic Reagents 2.4.2 Immune Diagnostic Reagents 2.4.3 Molecular Diagnostic Reagents 2.4.4 Integrated In Vitro Diagnostic Reagents 2.5 Profitability 2.6 Entry Barriers 2.6.1 Technical Barriers 2.6.2 Quality and Brand Barriers 2.6.3 Marketing Channel Barriers 2.6.4 Market Access Barriers 3. Development Environment of China Diagnostic Reagent Industry 3.1 Policy Environment 3.1.1 Regulatory Policy 3.1.2 Industry Policy 3.2 Upstream and Downstream Industries 3.2.1 Industrial Chain 3.2.2 Upstream 3.2.3 Downstream 4. Development Forecast of China Diagnostic Reagent Industry 4.1 Overall Forecast 4.1.1 Market Demand Drivers 4.1.2 Market Scale Forecast 4.2 Development Trends of Diagnostic Reagent Industry 4.2.1 Biochemical Diagnosis and Immunodiagnosis Will Still Be the Mainstream 4.2.2 Industry Concentration Will Increase 4.2.3 Enterprises with Complete Product Line Integrating Reagents and Instruments will Win 5. Major Chinese Diagnostic Reagent Enterprises

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs